Drug intelligence / Profile preview

Jian Shen Pian

Development stage: Unknown
Lead developer: Jiangsu Kanion Pharmaceutical
Administration: Oral

Overview

Jian Shen Pian is a traditional Chinese medicine (TCM) oral tablet developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic nephritis, specifically targeting the Pi-Shen (Spleen-Kidney) deficiency pattern. The formulation is designed to reduce subnephrotic proteinuria and improve clinical symptoms associated with chronic glomerulonephritis. In clinical studies, it has been evaluated for its ability to tonify the spleen and kidney, resolve dampness, and improve renal function. A Phase 3 trial (CTR20130167) in China compared Jian Shen Pian against Shenyanshu capsules in adult patients to establish its safety and efficacy profile.

Brand names: Jian Shen Pian
Other names: Jianshen PianJianshen Tablet

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Jian Shen Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jian Shen Pian.

Explore the full profile